GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off

Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications can identify a subgroup of patients with T2D at high risk of mortality who are likely to achi...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliano, Dario, Scappaticcio, Lorenzo, Longo, Miriam, Bellastella, Giuseppe, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513211/
https://www.ncbi.nlm.nih.gov/pubmed/34641876
http://dx.doi.org/10.1186/s12933-021-01400-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513211/
https://www.ncbi.nlm.nih.gov/pubmed/34641876
http://dx.doi.org/10.1186/s12933-021-01400-9

Ejemplares similares